- Lenacapavir is the first injectable PrEP for HIV, administered every 6 months.
- It targets multiple stages of the HIV lifecycle and demonstrated high efficacy in preventing HIV infection.
- Common side effects include injection site reactions, headache, and nausea.
- A negative HIV-1 test is required before each injection, with a boxed warning about the risk of drug resistance.
- Lenacapavir can remain in the body for up to 12 months after the last dose.
- It may help increase access to PrEP in the US, especially in underserved populations.
- Assistance programs for access to lenacapavir are available for insured and uninsured individuals.
- Lenacapavir is also approved for the treatment of multidrug-resistant HIV.
Source: GILEAD
